Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05556928 · ClinicalTrials.gov registry record

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

A clinical trial of Multiple Myeloma and Amyloidosis, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
5,000
Enrollment target
1
Study location

NCT05556928: Recruiting study of Multiple Myeloma and Amyloidosis, sponsored by University of Alabama at Birmingham.

NCT05556928 is a study of Multiple Myeloma and Amyloidosis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 5,000 participants, above the 535-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (835% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05556928, a study of Multiple Myeloma and Amyloidosis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at UAB and to gather information that would lend support for future research in this vulnerable population.

Primary Outcome

To establish and maintain a well-annotated registry (to be called the 'CARE-Heme' Registry) of adults ≥50 years of age with a hematologic malignancy to improve our understanding of this vulnerable population.

Study Locations (1)

Alabama

  • Kirklin Clinic of UAB Hospital - Birmingham

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2020-07-21
Est. Completion 2027-12-31
University of Alabama at Birmingham

1,160 total trials

What NCT05556928 shows while recruiting

NCT05556928 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 535-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (835% higher).

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.

NCT05556928 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT05556928 about?

NCT05556928 is a clinical study titled "Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry". The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and geriatric impairments among patients aged ≥50y and above diagnosed with a hematologic malignancy at U...

What is the current status of trial NCT05556928?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2020-07-21. Estimated completion is 2027-12-31.

What conditions does trial NCT05556928 study?

This clinical trial studies the following conditions: Multiple Myeloma, Amyloidosis, Plasma Cell Leukemia.

Who is sponsoring clinical trial NCT05556928?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05556928 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05556928's enrollment target sits among peer trials

5,000 5th of 438 higher than 432 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00991094 · 5,000 participants

    Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05556928, the US trial registry maintained by the National Library of Medicine. NCT05556928 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.